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Abstract
Therapeutic strategies are often based on two general principles: interference with the pathogenic
process and repair the damaged tissues. Recent studies, however, have suggested that several
pathological conditions may result from the interplay between genetic susceptibility traits and
environmental influences that, by modulating the epigenome, also affect disease onset and
progression. Based on lessons learned from neural development, it is conceivable that new lines of
preventive and possibly therapeutic intervention might be developed in the future in order to
modulate disease onset or decrease the severity of the symptoms. This review will discuss these
concepts within the context of multiple sclerosis (MS), the most common demyelinating disease of
the central nervous system (CNS), and the leading cause of progressive neurological disability in
young adults.
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INTRODUCTION
Multiple sclerosis is defined as an inflammatory demyelinating disorder affecting the young
adult population (Compston & Coles, 2008), typically affecting individuals between the age
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of 20 and 45 years of age, although the occurrence of pediatric MS is on the rise. Clinical
symptoms are variable, depending on the involvement of visual, sensory or motor pathways,
and include but are not limited to: ataxia, fatigue, cognitive impairment or autonomic
manifestations. A large proportion of patients (~ 80%) develops a relapsing-remitting
(RRMS) course of the disease, characterized by acute relapses and long stretches of
symptom-free periods (called “remissions”), while a smaller proportion (~ 10–15%) of the
patients do not return to baseline conditions and accumulate disability over time (primary
progressive form of the disease). Eventually, the relapsing-remitting course of the disease
will enter a phase of incomplete recovery, when the symptoms persist and neurological
function deteriorates over time, defining the secondary progressive (SPMS) phase of the
disease (Thompson et al., 1997; Rovaris et al., 2006). The challenge of this manuscript is to
review the current studies available in the literature and propose an integrated view of
disease pathogenesis, with the aim of opening a debate regarding the feasibility of future
potential integrated approaches to therapy.
1. Multiple Sclerosis as an autoimmune disease
Most of the current knowledge on the etio-pathogenesis of MS is derived from a large
number of epidemiological, histopathological, immunological and genetic studies.
Inflammation, demyelination, and axonal degeneration are the major pathologic features of
MS (Compston & Coles, 2008). It is well accepted that MS prevalence increases with
latitude (Alonso & Hernan, 2008) and that its incidence is higher in people with low levels
of vitamin D and low sun exposure (Ascherio & Munger, 2007). Its onset has also been
associated with viral infections by Epstein-Barr virus and possibly related to additional
strains of herpesviruses (Kakalacheva et al., 2011). However, there has been no conclusive
evidence that any of these factors, per se, is capable of inducing the disease. Rather, viral
infections, low vitamin D levels, stress, diet and other life style changes have been proposed
to act as co-factors to trigger disease onset in genetically susceptible individuals.
Identifying susceptibility genes for MS has been a subject of intense research since early
1970s when genes encoding for class II alleles of the major histocompatibility complex
(MHC) were first identified (Jersild et al., 1973; Compston et al., 1976; Terasaki et al.,
1976). Consequent gene linkage studies in multiplex families and genetic association
studies, fine-mapped this region to the HLA-DR15 haplotype (Fogdell et al., 1995) and
suggested the existence of a gradient on susceptibility to MS depending on the specific
combination of allelic variants within this locus (Rasmussen et al., 2001; Dyment et al.,
2005). In addition, specific MHC class I alleles showed an independent association and
modulation of the risk on HLA-DR15 haplotype carriers, with HLA-A3 allele as risk-
increasing and HLA-A2 as risk-decreasing allele (Fogdell-Hahn et al., 2000; Harbo et al.,
2004; Friese et al., 2008). Further genome-wide association studies (GWAS), analyzing
>100,000 single nucleotide polymorphism (SNP) markers, identified additional non-MHC
polymorphisms related to MS risk and highlighted the importance of the MHC class II
region on disease susceptibility (Lincoln et al., 2005; Sawcer et al., 2005; Burton et al.,
2007; Hafler et al., 2007; Friese et al., 2008; Baranzini et al., 2009; The Australian and New
Zealand Multiple Sclerosis Genetics Consortium 2009; De Jager et al., 2009a). Most of the
non-MHC genes identified by these studies related to the immune system and had been
previously associated with increased susceptibility to autoimmune disorders. Among them,
interleukin-7 receptor alpha chain (IL7RA) and other genes in the IL7/IL7R axis showed
high association to MS (Hafler et al., 2007; De Jager et al., 2009b; Zuvich et al., 2010), and
therefore were identified as potential therapeutic targets (Sasson et al., 2006). Similarly, the
association of the interleukin-2 receptor alpha chain (IL2RA) to MS (Hafler et al., 2007; The
Australian and New Zealand Multiple Sclerosis Genetics Consortium 2009; De Jager et al.,
2009b) led to the development of monoclonal antibodies against this protein which are
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currently being assessed in small clinical trials (Schippling & Martin, 2008). An additional
polymorphism associated with MS includes the SNP rs2300747 in the CD58 gene (Hafler et
al., 2007; The Australian and New Zealand Multiple Sclerosis Genetics Consortium, 2009;
De Jager et al., 2009b), which is critical for regulation of T-cell receptor signaling. Higher
levels of CD58 transcripts were detected in remitting MS patients and this allele was
associated with a protective effect on MS progression (De Jager et al., 2009a).
While a thorough review of the genetic studies is above and beyond the scope of this article,
we would like to mention that a recent collaborative study including 9,772 cases recruited by
23 Centers worldwide, including the US, Australia and several European countries (Sawcer
et al., 2011) confirmed the critical importance of HLA-DRB1 as risk alleles and validated
several genes involved in cytokine signaling, including IL2, IFN gamma, IL-12, TNF alpha
and IL6 pathways as genes associated with the disease.
Together, the vast literature on the GWAS studies identified the immune system as the
primary system modulated by susceptibility genes. We believe that an integrated review of
the distinct loci might lead to the development of panels of candidate susceptibility genes
that may contribute to a better diagnostic classification of patients ad potentially identify
individuals that are more likely to benefit from therapies targeting a specific pathway, such
as the IL7 (Sasson et al., 2006) or IL2 (Schippling & Martin, 2008) pathway.
2. Immune-based animal models of demyelination to test therapeutic approaches in MS
The rodent model for MS, experimental autoimmune encephalomyelitis (EAE), is one of the
most extensively studied animal models of immune disease to identify the molecular
mechanisms involved in the inflammatory response and to assess the validity of new
therapies for MS. The origins of this model go back to 1885 when Louis Pasteur's rabies
vaccine was first used clinically and some cases of paralysis were reported subsequently
(reviewed in (Baxter, 2007)). Since the first studies, it has evolved with current
immunizations with whole brain emulsions and myelin proteins or peptides. Immunization
of the animals with these compounds leads to a disease that shares clinical and
neuropathological changes with MS (Steinman, 1999). Most therapies tested in MS patients
are based on concepts derived from studies in EAE, but unfortunately an important number
of potential therapies that showed effectiveness in this model, failed to demonstrate a
positive effect in patients. This can be explained by the fact that the artificial immunization
of the animals may not necessarily reproduce all the pathogenic mechanisms in human
disease so animal models should be adapted to account for the genetic variability shown in
MS. It has been noted that the genetic background of different mouse strains influences the
disease course in the EAE model (Miller et al., 2010). Based on these consideration, the
development of partially humanized mouse models represents a promising tool to address
the influence of the genetic component in disease onset and progression (Gregersen et al.,
2004). Transgenic mice expressing MHC-class II molecules and T-cell receptor variants
from MS patients may better represent many of the various clinical manifestations and
corresponding CNS lesions of MS (Madsen et al., 1999; Quandt et al., 2004). While we
appreciate the effort in the generation of humanized transgenic mice, we recognize that this
is a very powerful and promising strategy for testing and propose that it would be fully
exploited to test proof-of-principle concepts for the involvement of pathways identified by
the large GWAS studies.
3. Pharmacogenomic approaches to “personalized” medicine
Growing evidence shows that the clinical response to MS therapies varies widely among
patients (Miller et al., 2008) and thus the paradigm of “one drug fits all” has been shifted
towards the search for a more “personalized” therapy. Pharmacogenomic studies focus on
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the identification of genetic variations that have an influence on drug response, in the end
aiming at the identification of the patients who will show a more effective response to
therapy and will present less adverse side effects. This area has already gained great
importance since many FDA-approved drugs currently show pharmacogenomic information
in its labels
(http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/
ucm083378.htm). Some of these drugs are used in cancer, viral infections, neurologic and
cardiovascular diseases. In many cases the genetic markers identified belong to the
cytochrome P450 family, related to the pharmacokinetics (metabolism and clearance) of the
drugs, and thus individual variations could affect the effectiveness, adverse events and drug
interactions of these treatments. Other examples of markers are different receptors whose
expression in several types of tumors is assessed in the clinical practice in order to prescribe
antagonists that will be effective in the treatment of the disease. Among them are the
detection of estrogen receptors (ER) in breast cancer and epidermal growth factor receptor
(EGFR) for colorectal cancer. In other cases, the expression of certain variants of genes will
confer great response to certain drugs, such as the allele rs12979860 of interferon-lambda-3
gene (IL28B) for the treatment of hepatitis C. Regarding MS treatment, Azathioprine (AZA)
is an immunosuppressive drug used as an alternative to interferon-beta and also indicated in
other neuroimmunological diseases. The most severe adverse effect is hematological toxicity
that can be fatal in about 0.3% of cases (Connell et al., 1993). Methylation by thiopurine-
methyl transferase (TPMT) is the limiting step for the inactivation of AZA. Therefore, the
FDA recommends TPMT genotyping and/or phenotyping prior prescribing AZA treatment,
being contraindicated in patients with low or absent TPMT activity (0.3% of the cases).
Dose escalation is recommended for intermediate metabolizing enzymes (10%). Several
pharmacogenomic studies have identified diverse genetic variants for other disease-
modifying therapies for MS but further investigations needs to be addressed in order to find
strong evidence for these observations. Among them, several polymorphisms in interferon
(IFN) pathway and IFN-beta responsive genes (e.g. interleukin-17) have been associated
with response to this drug, as well as other neurogenesis (GPC5, glypican 5; NPAS3,
neuronal PAS domain protein 3) and neurotransmission related genes (AMPA type
glutamate receptor GRIA3) (Cunningham et al., 2005; Martinez et al., 2006; Byun et al.,
2008; Comabella et al., 2009; Axtell et al., 2010). In addition, responsiveness to glatiramer
acetate (GA) treatment has been linked to HLA-DRB1*1501, rs71878 for T-cell receptor-
beta and rs2275235 for cathepsin S (CTSS) (Fusco et al., 2001; Grossman et al., 2007).
Finally, several polymorphisms in the adenosine triphosphate (ATP)-binding cassette
(ABC)-transporter genes have also been identified as potential predictors for clinical
response and toxicity of the immunosuppressant mitoxantrone (Cotte et al., 2009; Dorr et al.,
2009).
In conclusion, pharmacogenomic studies are contributing to the achievement of a
“personalized” therapy for different disorders. The hope is that more data will be available
for MS and lead to the creation of platforms that could be used to better stratify the patient
population and possibly inform therapeutic decisions.
4. Environmental effects on individuals with genetic traits induce disease onset and
related animal models
While the genetic evidence implying an effect of the immune system in disease onset, is
irrefutable, it is undoubtedly significant to note that not all the individuals with a given risk
allele, develop the disease. In this respect, it is worth noting that even identical twins are
only 30% concordant for the development of the disease (Hawkes & Macgregor, 2009).
What are the factors that allow individuals with the same genetic risk factor to develop or
not develop the disease? One of the potential explanations, based on the epidemiological
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data, is that additional environmental components are needed in order to develop the disease.
The concept of genetic susceptibility, was described by Poser as “the MS trait” that would
manifest itself only if additional events would take place (Poser, 2006). This is an attractive
hypothesis that is quite reminiscent of the two-hits cancer model proposed by Knudson
(Knudson, 2001). Low sun exposure, low vitamin D levels, stressful situations, viral
infections, they could all contribute to trigger the disease in predisposed individuals (Lauer,
2010). A very interesting correlation between MS and diet has also been proposed
(Ghadirian et al., 1998) and related to the consumption of cow milk products in countries
with high incidence of MS(Guggenmos et al., 2004). The effect of diet on influencing
disease onset in a group of genetically susceptible individuals has been reported in children
with type I diabetes, where those that were fed an omega 6 rich diet developed the disease,
while the group that was fed an omega 3 rich diet was protected (Norris et al., 2007).
An interesting model to test the hypothesis of the link between diet and demyelination is
provided by the cuprizone model. Feeding mice with a diet containing 0.2% of the copper
chelators cuprizone, results in oligodendrogliopathy followed by myelin loss, microglial
infiltration and astrogliosis (Matsushima & Morell, 2001). Furthermore, removal of the
toxicant from the diet results in recovery of the lesions due to spontaneous remyelination.
Aged mice are more prone to axonal degeneration upon cuprizone-induced demyelination
(Irvine & Blakemore, 2006). Previous studies in our laboratory have used this model to test
the effect of age in modulating myelin repair (Shen et al., 2008). Some studies reported a
lower extent of cuprizone-induced demyelination in SJL mice compared to C57BL/6 strain
(Taylor et al., 2009), highlighting the importance of this model to study the role of genetic
susceptibility in the development of a pathology induced by dietary intake of the copper
chelator. To further address the interplay between genetic traits and external dietary factors,
we fed eight distinct mouse strains with the same diet for the same period of time and then
assessed the levels of demyelination and microglial activation. Quantitative RT-PCR and
immunohistochemistry analyses of corpus callosum showed that two mouse strains (i.e.
DBA and A/J mice) were highly sensitive to cuprizone, as evidenced by decreased levels of
the myelin protein CNPase in the corpus callosum (Figure 1A and B). Consistent with the
specific effect of cuprizone in the corpus callosum, the effect was only observed in this area
and not in the spinal cord (Figure 1C). In contrast, NOD mice did not respond to the
cuprizone diet evidenced by no decrease in CNPase, indicating that different genetic
backgrounds affect the susceptibility to develop a demyelinating pathology in response to
dietary manipulations. Previous studies also reported differences in microglia infiltration in
the corpus callosum of BALB and C57BL/6 mice, even in the presence of similar
demyelination patterns in this specific region (Skripuletz et al., 2008). In order to determine
if microglial activation could account for the differences observed in our experiments, we
examined mRNA levels of microglial activators, including chemokine L3 (Chem3),
lysozyme, beta2-microglobulin, TNFalpha and cathepsin Z in the strains showing greater
differences in CNPase levels (Figure 1D–H). In general, a greater activation was observed in
A/J mice, which could partially explain the higher sensitivity of this strain to cuprizone
action. Strikingly however, DBA mice showed a milder microglial activation pattern,
thereby revealing a pattern of extreme sensitivity to cuprizone diet in this strain. In support
of a dissociation between microglial activation and demyelination, the NOD mice which
represented the most resistant strain to cuprizone diet, also had a significant microglial
activation (Figure 1D and E). Together, these experiments reveal a highly heterogeneous
response to dietary cuprizone that depends on the individual genetic background. In
connection with the findings mentioned previously in this section these data support the
importance of the interplay between intrinsic (i.e. genetic) and extrinsic (i.e. diet) factors in
the onset of demyelinating diseases.
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5. Importance of early intervention to prevent disease onset
The geographic distribution of the incidence and prevalence of MS varies with increasing
risk at higher latitudes (Alonso & Hernan, 2008). Interestingly, adults migrating from a high
to low risk area are thought to carry their former high risk with them, whereas people who
migrate during childhood seem to have the risk associated to the new area to which they
migrated (Dean, 1971; Alter et al., 1978; Elian et al., 1990; Cabre et al., 2005). These
observations implicate an environmental event involved in MS pathogenesis which acts
sometime between birth and young adulthood but does not act thereafter. It is also believed
that even environmental factors during preborn life can influence MS risk. There is evidence
of a month-of-birth effect on MS reported in Canada and northern Europe, with more
patients born in May and fewer in November (Templer et al., 1992; Willer et al., 2005;
Sadovnick et al., 2007). Many environmental factors have been proposed to be linked to MS
pathogenesis including Epstein-Barr virus (EBV) and other virus infection, vitamin D
deficiency, low-sunlight, occupational hazards, living with domesticated animals, dietary
habits, trauma, stress and toxic exposures (Compston et al., 2005). Among them, however,
vitamin D deficiency and EBV infection have been gaining the greatest support for their
potential role in MS pathogenesis. A careful control of these variables in childhood, for
instance by providing adequate vitamin D3 supplementation and monitoring its levels in
individuals at high genetic risk, is crucial in the determination of the disease course (Figure
2).
6. Epigenetic changes detected during neural development may inform therapies later in
life
Our laboratory has previously characterized important mechanisms of regulation of
developmental myelination that depend on the modification of chromatin components. We
have shown that the activity of chromatin-modifying enzymes called HDACs is essential for
oligodendrocyte differentiation in vitro (Marin-Husstege et al., 2002) and in vivo (Shen et
al., 2005). We have then extended this work to the analysis of mechanisms of remyelination
in the adult brain (Shen et al., 2008). We previously demonstrated that HDAC enzymatic
activity is necessary for oligodendrocyte differentiation because it decreases the levels of
inhibitors of oligodendrocyte process outgrowth (i.e. stathmin) (Liu et al., 2003; Liu et al.,
2005) and of myelin gene expression (i.e. Id4, Hes5) (Gokhan et al., 2005; Marin-Husstege
et al., 2006). The use of HDAC inhibitors (HDACi) for MS treatment has been proposed
based on their approved use as anti-cancer agents (Marks et al., 2001). However, the use of
HDACi for treatment of MS is more controversial since studies on the animal EAE model of
demyelination have shown results in both directions (Natarajan & Bright, 2002; Camelo et
al., 2005). We also reported the negative effects of treatment with pharmacological blockers
of HDAC on oligodendrocyte progenitor differentiation in vitro (Marin-Husstege et al.,
2002) and on developmental myelination in vivo (Shen et al., 2005) and during myelin
repair after cuprizone-induced demyelination (Shen et al., 2008). We also described the
occurrence of similar mechanisms in the adult MS human brain (Pedre et al., 2011) and
therefore would like to caution against the use of HDAC inhibitors during a specific time
period, which coincides with the early stages of oligodendrocyte differentiation and myelin
repair. The involvement of epigenetic changes, particularly in terms of chromatin
modifications, is exciting for two reasons. First, it sheds light on the etiology of the early
aspects of the disease process. Second, and perhaps more importantly, it may provide insight
to understand how environmental factors can influence disease development and acquisition
even in genetically identical patients. This insight comes from the fact that epigenetic
changes in the brain have been documented to change significantly over the lifetime of
individuals (Hernandez et al., 2011), and to diverge significantly in identical twins (Fraga et
al., 2005).
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As a summary, in this article we have reviewed the different factors that contribute to MS
susceptibility, including genetic variants and environmental factors, and have pointed that
populations which build up several of these risk factors could be eligible for early
therapeutic interventions in order to prevent the onset or lessen the severity of the disease.
We now propose to integrate the currently available information, into the development of
two stage-treatment platforms. The first stage would include a careful stratification of
patients, based on vitamin D3 levels and based on the results of genetic screens, designed on
the basis of the currently available GWAS data sets. The second stage would include
pharmacological and environmental intervention, aimed at promoting repair. This would be
best achieved by taking into account genotypes associated with greater responsiveness or
resistance to specific treatments, while awaiting for the development of targeted epigenomic
approaches.
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Figure 1. Different susceptibility of mouse strains to cuprizone-induced demyelination
Eight different mouse strains were fed a diet containing 0.2% cuprizone during 4 weeks.
Total RNA from freshly dissected corpus callosum (A) and spinal cord (C) was isolated and
CNP levels analyzed by quantitative RT-PCR. Values obtained were normalized to GAPDH
transcript levels and the bar graphs represent the normalized values relative to those
measured in the corpora callosa of C57BL/6 mice. (B) Immunofluorescence micrograph of
coronal brain sections of DBA, A/J and NOD mice, immunostained with the antibody
against the myelin protein CNPase (red) and the nuclear stain DAPI (blue). Images show the
corpus callosum. V=ventricle; scale bar =100 μm. (D-H) Quantitative PCR analyses of the
same three mouse strains for different microglial activators normalized to GAPDH transcript
levels and expressed relative to the values measured in DBA controls. Statistical differences
for all qRT-PCR analyses were determined using two-tailed independent t-tests with
Bonferroni correction (*P < 0.05, **P < 0.01, ***P < 0.001).
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Figure 2. Multiple sclerosis is a complex disease with cumulative risk factors leading to its onset
In addition to genetic predisposition, one or more environmental events need to occur in
order for MS to develop. The time sequence and age of incidence of each factor appears to
play a role in disease development. There is growing evidence of an epigenetic mechanism
driven by the different environmental risk factors, so it is conceivable that epigenetic
modulators could be used during early stages of life to prevent MS onset or during the early
stages of the pathology to decrease the severity of the symptoms.
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